Efficacy of alemtuzumab in organ transplantation: Current clinical status

Gaetano Ciancio*, George W. Burke, Maria E. Warque, Joshua Miller

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


An overview of the past 5 years of clinical renal transplantation would include progress in (i) the development of protocols with new induction agents (non-depleting versus depleting monoclonal and polyclonal antibodies) designed to reduce the incidence and severity of acute rejection, (ii) the attempt to reduce calcineurin inhibitor short- and long-term nephrotoxicity, and (iii) the attempt to reduce immunosuppression overall if an immunoregulatory state ('tolerance') against donor alloantigens could be achieved. One such induction agent is the humanized anti-CD52 monoclonal antibody alemtuzumab (Campath-1H), which depletes T cells (most potently), as well as B cells and other lymphoid subsets, and may decrease the dosage or need for concurrent maintenance immunosuppressive agents.

Original languageEnglish (US)
Pages (from-to)85-92
Number of pages8
Issue number2
StatePublished - Jan 1 2006

ASJC Scopus subject areas

  • Biotechnology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Efficacy of alemtuzumab in organ transplantation: Current clinical status'. Together they form a unique fingerprint.

Cite this